Berberine: A Potential Multipotent Natural Product to Combat Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
With the accelerated aging of human society Alzheimer’s disease (AD) has become one of the most threatening diseases in the elderly. However, there is no efficient therapeutic agent to combat AD. Berberine is a natural isoquinoline alkaloid that possesses a wide range of pharmacological effects. In the present paper, we review the multiple activities of berberine, including antioxidant, acetylcholinesterase and butyrylcholinesterase inhibitory, monoamine oxidase inhibitory, amyloid-b peptide level-reducing and cholesterol-lowering activities, which suggest that berberine may act as a promising multipotent agent to combat AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683 · cited 3×
“It has been widely recognized that oxidative damage plays an important role in the pathogenesis of AD [5,19-22].”
BackgroundBlennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“[5-10], to screen drugs to treat this disease.”
BackgroundBallard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932 · cited 1×
“As the most common form of dementia, Alzheimer’s disease (AD) has been one of the most threatening diseases in the elderly with the accelerated aging of human society [1-4].”
BackgroundKong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
Cummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Neuroinflammation, Oxidative Stress and the Pathogenesis of Alzheimers Disease
Agostinho, P., A. Cunha, R., & Oliveira, C. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210793176572 · Cited by 685 · cited 2×
“It has been widely recognized that oxidative damage plays an important role in the pathogenesis of AD [5,19-22].”
BackgroundTreatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine
Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Huo, L., Wang, M., Hong, J., Wu, P., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2404 · Cited by 573 · cited 1×
“The efficacy and safety of berberine in the treatment of type 2 diabetes have been reported [53,54], which reinforces the anti-AD potential of berberine.”
BackgroundButterfield, D. A., Reed, T., Newman, S. F., & Sultana, R. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.05.037 · Cited by 564
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?
Akter, K., Lanza, E. A., Martin, S. A., Myronyuk, N., Rua, M., & Raffa, R. B. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03830.x · Cited by 352
Cholesterol and the Biology of Alzheimer's Disease
Wolozin, B. (2004) · Neuron · doi:10.1016/s0896-6273(03)00840-7 · Cited by 275
Pereira, G. C., Branco, A. F., Matos, J. A. C., Pereira, S. L., Parke, D., Perkins, E. L., Serafim, T. L., Sardão, V. A., Santos, M. S., Moreno, A. J. M., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.128017 · Cited by 152
The Role of GLP-1 in Neuronal Activity and Neurodegeneration
Hölscher, C. (2010) · Vitamins & Hormones · doi:10.1016/b978-0-12-381517-0.00013-8 · Cited by 74 · cited 1×
“GLP-1 has been proved to protect neurons from toxic effects and proposed as a novel therapeutic target for intervention in AD [56,57].”
Background
Cited by
The metabolism of berberine and its contribution to the pharmacological effects
Wang, K., Feng, X., Chai, L., Cao, S., & Qiu, F. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2017.1306544 · Cited by 502
Mushtaq, G., Greig, N., Khan, J., & Kamal, M. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141023141545 · Cited by 331
Durairajan, S. S. K., Liu, L.-F., Lu, J.-H., Chen, L.-L., Yuan, Q., Chung, S. K., Huang, L., Li, X.-S., Huang, J.-D., & Li, M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.02.016 · Cited by 271
Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202
Pharmacological effects of berberine and its derivatives: a patent update
Jin, Y., Khadka, D. B., & Cho, W.-J. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1118060 · Cited by 174
Metadata
- Authors
- Ji, H.-F., & Shen, L.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2011-08-09
- Volume
- 16
- Issue
- 8
- Pages
- 6732-6740
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W1985647802
- Cited by
- 166
- References
- 15
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.